<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33677821</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2107-0180</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>46</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>European journal of drug metabolism and pharmacokinetics</Title>
          <ISOAbbreviation>Eur J Drug Metab Pharmacokinet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients.</ArticleTitle>
        <Pagination>
          <StartPage>353</StartPage>
          <EndPage>371</EndPage>
          <MedlinePgn>353-371</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s13318-021-00673-5</ELocationID>
        <Abstract>
          <AbstractText Label="UNLABELLED">BACKGROUND AND OBJECTIVE: Prior olanzapine population pharmacokinetic (PPK) models have focused on the effects of sex and smoking on olanzapine clearance. This PPK model in Chinese adult psychiatric patients also investigated the influence of comedications and co-occurrence of infections on olanzapine clearance, and explored how to personalize oral olanzapine dosage in the clinical setting.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">A total of 1546 serum concentrations from 354 patients were collected in this study. A one-compartment model with first-order absorption was employed to develop the PPK model using a nonlinear mixed-effects modeling approach. Covariates included demographic parameters, co-occurrence of infection and concomitant medications (including dangguilonghui tablets, a Chinese herbal medicine for constipation). Bootstrap validation (1000 runs) and external validation of 50 patients were employed to evaluate the final model. Simulations were performed to explore the personalization of olanzapine dosing after stratification by sex, smoking, and comedication with valproate.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Typical estimates for the absorption rate constant (K<sub>a</sub>), apparent clearance (CL/F), and apparent distribution volume (V/F) were 0.30 h<sup>-1</sup>, 12.88 L/h, and 754.41 L, respectively. Olanzapine clearance was increased by the following variables: 1.23-fold by male sex, 1.23-fold by smoking, 1.23-fold by comedication with valproate, 1.16-fold by sertraline, and 2.01-fold by dangguilonghui tablets. Olanzapine clearance was decreased by the following variables: 0.75-fold by co-occurrence of infection, 0.70-fold by fluvoxamine, and 0.78-fold by perphenazine. The model evaluation indicated that the final model's performance was good, stable, and precise.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study contributes to the personalization of oral olanzapine dosing, but further studies should be performed to verify the effects of infection and comedications, including valproate and dangguilonghui.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zang</LastName>
            <ForeName>Yan-Nan</ForeName>
            <Initials>YN</Initials>
            <Identifier Source="ORCID">0000-0002-9058-5705</Identifier>
            <AffiliationInfo>
              <Affiliation>The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, No. 5 Ankang Lane, Dewai Avenue, Xicheng District, Beijing, 100088, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dong</LastName>
            <ForeName>Fang</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, No. 5 Ankang Lane, Dewai Avenue, Xicheng District, Beijing, 100088, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>An-Ning</ForeName>
            <Initials>AN</Initials>
            <AffiliationInfo>
              <Affiliation>The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, No. 5 Ankang Lane, Dewai Avenue, Xicheng District, Beijing, 100088, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Chuan-Yue</ForeName>
            <Initials>CY</Initials>
            <Identifier Source="ORCID">0000-0001-6549-3713</Identifier>
            <AffiliationInfo>
              <Affiliation>The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, No. 5 Ankang Lane, Dewai Avenue, Xicheng District, Beijing, 100088, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Gui-Xin</ForeName>
            <Initials>GX</Initials>
            <AffiliationInfo>
              <Affiliation>The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, No. 5 Ankang Lane, Dewai Avenue, Xicheng District, Beijing, 100088, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Qian</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, No. 5 Ankang Lane, Dewai Avenue, Xicheng District, Beijing, 100088, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yan-Fang</ForeName>
            <Initials>YF</Initials>
            <AffiliationInfo>
              <Affiliation>The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, No. 5 Ankang Lane, Dewai Avenue, Xicheng District, Beijing, 100088, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, No. 5 Ankang Lane, Dewai Avenue, Xicheng District, Beijing, 100088, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Leon</LastName>
            <ForeName>Jose</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-7756-2314</Identifier>
            <AffiliationInfo>
              <Affiliation>Mental Health Research Center at Eastern State Hospital, 1350 Bull Lea Road, Lexington, KY, 40511, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, University of Granada, Granada, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Centre in Mental Health Net (CIBERSAM), Santiago Apóstol Hospital, University of the Basque Country, Vitoria, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruan</LastName>
            <ForeName>Can-Jun</ForeName>
            <Initials>CJ</Initials>
            <Identifier Source="ORCID">0000-0002-1625-7367</Identifier>
            <AffiliationInfo>
              <Affiliation>The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, No. 5 Ankang Lane, Dewai Avenue, Xicheng District, Beijing, 100088, China. rcjjenny@ccmu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China. rcjjenny@ccmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D023361">Validation Study</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>France</Country>
        <MedlineTA>Eur J Drug Metab Pharmacokinet</MedlineTA>
        <NlmUniqueID>7608491</NlmUniqueID>
        <ISSNLinking>0378-7966</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>N7U69T4SZR</RegistryNumber>
          <NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Eur J Drug Metab Pharmacokinet. 2021 Mar 20;:</RefSource>
          <PMID Version="1">33743172</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044466" MajorTopicYN="N">Asians</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007239" MajorTopicYN="N">Infections</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012907" MajorTopicYN="N">Smoking</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherAbstract Type="plain-language-summary" Language="eng">
        <AbstractText>This study included a total of 1546 serum olanzapine concentrations from 354 Chinese adult psychiatric patients that were analyzed by a complex mathematical model. The goal was to explore how oral olanzapine is eliminated from the body in Chinese psychiatric patients and how to personalize its dosing. Prior studies using similar complex mathematical models only studied the effects of sex and smoking on olanzapine elimination. This study also investigated the influence of co-occurrence of infection and comedications, including dangguilonghui tablets. This is a Chinese herbal medicine used to treat constipation, including constipation secondary to olanzapine treatment. Olanzapine elimination was increased by the following variables: 1.23-fold by male sex, 1.23-fold by smoking, 1.23-fold by comedication with valproate, 1.16-fold by sertraline, and 2.01-fold by dangguilonghui tablets. Olanzapine elimination was decreased by the following variables: 0.75-fold by co-occurrence of infection, 0.70-fold by fluvoxamine, and 0.78-fold by perphenazine. This study contributes to the improvement of oral olanzapine dosing personalization, but further studies are needed to verify the effects of infection and comedications, including valproate and dangguilonghui.</AbstractText>
      </OtherAbstract>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>7</Day>
          <Hour>20</Hour>
          <Minute>43</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33677821</ArticleId>
        <ArticleId IdType="doi">10.1007/s13318-021-00673-5</ArticleId>
        <ArticleId IdType="pii">10.1007/s13318-021-00673-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lindenmayer JP, Khan A, Iskander A, Abad MT, Parker B. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry. 2007;68(3):368–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17388705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tollefson GD, Sanger TM, Beasley CM, Tran PV. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry. 1998;43(11):803–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9611669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006;163(2):247–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16449478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou JG, Huang L, Jin SH, Xu C, Frey B, Ma H, et al. Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020;5(1):e000621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32079622</ArticleId>
            <ArticleId IdType="pmc">7046384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008;28(4):392–400.</Citation>
        </Reference>
        <Reference>
          <Citation>Ulcickas Yood M, Delorenze GN, Quesenberry CP Jr, Oliveria SA, Tsai AL, Kim E, et al. Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose? BMC Psychiatry. 2011;11:197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22171594</ArticleId>
            <ArticleId IdType="pmc">3264670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31303314</ArticleId>
            <ArticleId IdType="pmc">6891890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hattori S, Suda A, Miyauchi M, Shiraishi Y, Saeki T, Fukushima T, et al. The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine. BMC Psychiatry. 2020;20(1):72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32070304</ArticleId>
            <ArticleId IdType="pmc">7027321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Söderberg MM, Haslemo T, Molden E, Dahl ML. Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients. Pharmacogenom J. 2013;13(6):544–50.</Citation>
        </Reference>
        <Reference>
          <Citation>Perera V, Gross AS, Polasek TM, Qin Y, Rao G, Forrest A, et al. Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia. Expert Opin Drug Metab Toxicol. 2013;9(9):1115–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23641727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther. 1996;276(2):658–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8632334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheehan JJ, Sliwa JK, Amatniek JC, Grinspan A, Canuso CM. Atypical antipsychotic metabolism and excretion. Curr Drug Metab. 2010;11(6):516–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20540690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perry PJ, Lund BC, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol. 2001;21(1):14–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11199942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol. 1997;17(6):472–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9408810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1–02):e1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29390205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin A, Shang D, Wen Y, Li L, Zhou T, Lu W. Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis. Eur J Clin Pharmacol. 2016;72(8):933–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27117554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bigos KL, Pollock BG, Coley KC, Miller DD, Marder SR, Aravagiri M, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008;48(2):157–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18199892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bigos KL, Bies RR, Pollock BG, Lowy JJ, Zhang F, Weinberger DR. Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Mol Psychiatry. 2011;16(6):620–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21519338</ArticleId>
            <ArticleId IdType="pmc">3100476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng SH, Wang ZZ, Lu HY, Li L, Hu JQ, Zhu XQ, et al. A retrospective analysis of steady-state olanzapine concentrations in Chinese patients using therapeutic drug monitoring: effects of valproate and other factors. Ther Drug Monit. 2020;42(4):636–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32039940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol. 2007;63:537–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17370067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruan CJ, Zang YN, Wang CY, Cheng YH, Sun C, Spina E, et al. Clozapine metabolism in East Asians and Caucasians: a pilot exploration of the prevalence of poor metabolizers and a systematic review. J Clin Psychopharmacol. 2019;39:135–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30811372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spina E, Hiemke C, de Leon J. Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2016;12(4):407–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26878495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davies SJ, Mulsant BH, Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, et al. The impact of sertraline co-administration on the pharmacokinetics of olanzapine: a population pharmacokinetic analysis of the STOP-PD. Clin Pharmacokinet. 2015;54(11):1161–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25971243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Leon J, Ruan CJ, Schoretsanitis G, De Las CC. A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology. Psychother Psychosom. 2020;89(4):200–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32289791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Leon J. Future studies on the interaction between clozapine and valproic acid should aspire to include longitudinal designs and free valproate concentrations, and should consider that inducer and/or inhibitory effects may vary with time, the individual, and the auto-induction of valproic acid. Ther Drug Monit. 2020;42(1):159–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31633608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spina E, D’Arrigo C, Santoro V, Muscatello MR, Pandolfo G, Zoccali R, et al. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder. Ther Drug Monit. 2009;31(6):758–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19865002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang KC, Bell TD, Lauer BA, Chai H. Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet. 1978;1:1132–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">77421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Leon J, Ruan CJ, Verdoux H, Wang C. Clozapine is strongly associated with the risk of pneumonia and inflammation. Gen Psychiatr. 2020;33(2):e100183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32420521</ArticleId>
            <ArticleId IdType="pmc">7199914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Leon J, Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(6):1059–63.</Citation>
        </Reference>
        <Reference>
          <Citation>Scherf-Clavel M, Weidner A, Deckert J, Menke A, Unterecker S. Pathological concentration of C-reactive protein is correlated to increased concentrations of quetiapine, but not of risperidone, olanzapine and aripiprazole in a naturalistic setting. Pharmacopsychiatry. 2020;53(1):30–5.</Citation>
        </Reference>
        <Reference>
          <Citation>Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacomet Syst Pharmacol. 2012;1(9):e6.</Citation>
        </Reference>
        <Reference>
          <Citation>Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development—part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacomet Syst Pharmacol. 2013;2(4):e38.</Citation>
        </Reference>
        <Reference>
          <Citation>Upton RN, Mould DR. Basic concepts in population modeling, simulation, and model-based drug development: part 3—introduction to pharmacodynamic modeling methods. CPT Pharmacomet Syst Pharmacol. 2014;3(1):e88.</Citation>
        </Reference>
        <Reference>
          <Citation>Kiang TK, Sherwin CM, Spigarelli MG, Ensom MH. Fundamentals of population pharmacokinetic modelling: modelling and software. Clin Pharmacokinet. 2012;51(8):515–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28258394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pilla Reddy V, Kozielska M, Suleiman AA, Johnson M, Vermeulen A, Liu J, et al. Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia part I: the use of PANSS total score and clinical utility. Schizophr Res. 2013;146(1–3):144–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23473810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li A, Ji S, Yue W, Yan H, Dong F, Ruan C, et al. Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia. BMJ Open. 2018;8(8):e020070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30121590</ArticleId>
            <ArticleId IdType="pmc">6104801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lobo ED, Robertson-Plouch C, Quinlan T, Hong Q, Bergstrom RF. Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: population pharmacokinetic model. Paediatr Drugs. 2010;12(3):201–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20297865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao J, Shi Z, Zhu S, Li GQ, Yan R, Yao M. Influences of processed rhubarbs on the activities of four CYP isozymes and the metabolism of saxagliptin in rats based on probe cocktail and pharmacokinetics approaches. J Ethnopharmacol. 2013;145(2):566–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23207062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruan CJ, Guo W, Zhou M, Guo GX, Wang CY, Li WB, et al. Quantitative determination of risperidone, paliperidone and olanzapine in human serum by liquid chromatography–tandem mass spectrometry coupled with on-line solid-phase extraction. Biomed Chromatogr. 2018;32(7):e4209.</Citation>
        </Reference>
        <Reference>
          <Citation>Gong Y, Yang M, Sun Y, Li J, Lu Y, Li X. Population pharmacokinetic analysis of tacrolimus in Chinese cardiac transplant recipients. Eur J Hosp Pharm. 2020;27(e1):e12–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32296499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carrillo JA, Herráiz AG, Ramos SI, Gervasini G, Vizcaíno S, Benítez J. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol. 2003;23(2):119–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12640212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bozikas VP, Papakosta M, Niopas I, Karavatos A, Mirtsou-Fidani V. Smoking impact on CYP1A2 activity in a group of patients with schizophrenia. Eur Neuropsychopharmacol. 2004;14(1):39–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14659985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pollock BG, Wylie M, Stack JA, Sorisio DA, Thompson DS, Kirshner MA, et al. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol. 1999;39(9):936–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10471985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saiz-Rodríguez M, Belmonte C, Román M, Ochoa D, Jiang-Zheng C, Koller D, et al. Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants. Basic Clin Pharmacol Toxicol. 2018;123(4):474–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29723928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug–drug interactions. Curr Drug Metab. 2008;9(5):410–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18537577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mauri MC, Paletta S, Di Pace C, Reggiori A, Cirnigliaro G, Valli I, et al. Clinical pharmacokinetics of atypical antipsychotics: an update. Clin Pharmacokinet. 2018;57(12):1493–528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29915922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weigmann H, Gerek S, Zeisig A, Müller M, Härtter S, Hiemke C. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 2001;23(4):410–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11477325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Jong J, Hoogenboom B, van Troostwijk LD, de Haan L. Interaction of olanzapine with fluvoxamine. Psychopharmacology. 2001;155(2):219–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11401013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiemke C, Peled A, Jabarin M, Hadjez J, Weigmann H, Härtter S, et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol. 2002;22(5):502–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12352274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiu CC, Lane HY, Huang MC, Liu HC, Jann MW, Hon YY, et al. Dose-dependent alternations in the pharmacokinetics of olanzapine during co-administration of fluvoxamine in patients with schizophrenia. J Clin Pharmacol. 2004;44(12):1385–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15545309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spina E, de Leon J. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2014;10(5):721–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24494611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeon SW, Kim YK. Unresolved issues for utilization of atypical antipsychotics in schizophrenia: antipsychotic polypharmacy and metabolic syndrome. Int J Mol Sci. 2017;18(10):2174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">5666855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiu H, He Y, Zhang Y, He M, Liu J, Chi R, et al. Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan. Aust N Z J Psychiatry. 2018;52(12):1202–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30309245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999;27(9):1078–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10460810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M. Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder. Curr Med Res Opin. 2012;28(5):701–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22356118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houston JP, Ketter TA, Case M, Bowden C, Degenhardt EK, Jamal HH, et al. Early symptom change and prediction of subsequent remission with olanzapine augmentation in divalproex-resistant bipolar mixed episodes. J Psychiatr Res. 2011;45(2):169–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20541220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tohen M, Sniadecki J, Sutton VK, Degenhardt EK, Karagianis JL, Sagman D, et al. Number needed to treat or harm analyses of olanzapine for maintenance treatment of bipolar disorder. J Clin Psychopharmacol. 2009;29(6):520–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19910715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houston JP, Tohen M, Degenhardt EK, Jamal HH, Liu LL, Ketter TA. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. J Clin Psychiatry. 2009;70(11):1540–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19778495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Novick D, Gonzalez-Pinto A, Haro JM, Bertsch J, Reed C, Perrin E, et al. Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study. Pharmacopsychiatry. 2009;42(4):145–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19585393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tohen M, Vieta E, Goodwin GM, Sun B, Amsterdam JD, Banov M, Shekhar A, et al. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry. 2008;69(11):1776–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19014751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houston JP, Ahl J, Meyers AL, Kaiser CJ, Tohen M, Baldessarini RJ. Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex. J Clin Psychiatry. 2006;67(8):1246–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16965203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baker RW, Brown E, Akiskal HS, Calabrese JR, Ketter TA, Schuh LM, et al. Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. Br J Psychiatry. 2004;185:472–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15572737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Namjoshi MA, Risser R, Shi L, Tohen M, Breier A. Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid. J Affect Disord. 2004;81(3):223–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15337326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry. 2004;184:337–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15056579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003;160(7):1263–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12832240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002;159(6):1011–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12042191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tohen M, Chengappa KN, Suppes T, Zarate CA Jr, Calabrese JR, Bowden CL, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59(1):62–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11779284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vieta E, Reinares M, Corbella B, Benabarre A, Gilaberte I, Colom F, et al. Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharmacol. 2001;21(5):469–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11593070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Leon J, Diaz FJ, Spina E. Pharmacokinetic drug–drug interactions between olanzapine and valproate need to be better studied. J Clin Psychiatry. 2010;71(7):957–8.</Citation>
        </Reference>
        <Reference>
          <Citation>de Leon J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: a summary of the current state for clinicians. Rev Psiquiatr Salud Ment. 2015;8(2):97–115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25745819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Leon J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: pharmacological issues and further understanding. Rev Psiquiatr Salud Ment. 2015;8(3):167–88.</Citation>
        </Reference>
        <Reference>
          <Citation>de Leon J. False-negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology. Part I: focus on epilepsy. J Clin Psychopharmacol. 2014;34(2):177–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24525637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Leon J. False-negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology: part II: focus on bipolar disorder. J Clin Psychopharmacol. 2014;34(3):291–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24717257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos. 2007;35(7):1032–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17392393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vrzal R, Doricakova A, Novotna A, Bachleda P, Bitman M, Pavek P, et al. Valproic acid augments vitamin D receptor-mediated induction of CYP24 by vitamin D3: a possible cause of valproic acid-induced osteomalacia? Toxicol Lett. 2011;200(3):146–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21115105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Jong FA, van der Bol JM, Mathijssen RH, Loos WJ, Mathôt RA, Kitzen JJ, et al. Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity. Cancer Biol Ther. 2007;6(9):1368–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17873515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol. 2005;45(1):89–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15601809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiatry. 1994;36(7):487–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7811848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Longo LP, Salzman C. Valproic acid effects on serum concentrations of clozapine and norclozapine. Am J Psychiatry. 1995;152(4):650.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7694927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riesselman A, Strobl B, Cooley AT, de Leon J. A case report that suggested that aspirin’s effects on valproic acid metabolism may contribute to valproic acid’s inducer effects on clozapine metabolism. J Clin Psychopharmacol. 2013;33(6):812–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24113673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz FJ, Santoro V, Spina E, Cogollo M, Rivera TE, Botts S, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry. 2008;41(3):81–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18484549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz FJ, Eap CB, Ansermot N, Crettol S, Spina E, de Leon J. Can valproic acid be an inducer of clozapine metabolism? Pharmacopsychiatry. 2014;47(3):89–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24764199</ArticleId>
            <ArticleId IdType="pmc">4229130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McLaughlin DB, Andrews JA, Hooper WD, Cannell GR, Eadie MJ, Dickinson RG. Apparent autoinduction of valproate beta-oxidation in humans. Br J Clin Pharmacol. 2000;49(5):409–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10792197</ArticleId>
            <ArticleId IdType="pmc">2014955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lana F, Martí-Bonany J, de Leon J. Ibuprofen may increase pharmacological action of valproate by displacing it from plasma proteins: a case report. Am J Psychiatry. 2016;173(9):941–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27581700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lana F, Martí-Bonany J, Fuster J, de Leon J. Reduction in serum concentration of valproic acid secondary to the intake of ibuprofen as an example of valproic acid auto-induction metabolism. Actas Esp Psiquiatr. 2016;44(4):136–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27388105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackson J, McCollum B, Ognibene J, Diaz FJ, de Leon J. Three patients needing high doses of valproic acid to get therapeutic concentrations. Case Rep Psychiatry. 2015;2015:542862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26000191</ArticleId>
            <ArticleId IdType="pmc">4427013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergemann N, Kress KR, Abu-Tair F, Frick A, Kopitz J. Valproate lowers plasma concentration of olanzapine. J Clin Psychopharmacol. 2006;26(4):432–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16855466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haslemo T, Olsen K, Lunde H, Molden E. Valproic acid significantly lowers serum concentrations of olanzapine—an interaction effect comparable with smoking. Ther Drug Monit. 2012;34(5):512–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22972535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tveito M, Smith RL, Høiseth G, Molden E. The effect of valproic acid on olanzapine serum concentration: a study including 2791 patients treated with olanzapine tablets or long-acting injections. J Clin Psychopharmacol. 2019;39(6):561–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31688390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61(1):111–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11217867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol. 2005;1(4):629–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16863429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah RR, Smith RL. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine. Drug Metab Dispos. 2015;43(3):400–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25519488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haack MJ, Bak ML, Beurskens R, Maes M, Stolk LM, Delespaul PA. Toxic rise of clozapine plasma concentrations in relation to inflammation. Eur Neuropsychopharmacol. 2003;13(5):381–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12957337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfuhlmann B, Hiemke C, Unterecker S, Burger R, Schmidtke A, Riederer P, et al. Toxic clozapine serum levels during inflammatory reactions. J Clin Psychopharmacol. 2009;29(4):392–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19593184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruan CJ, Zhen XY, Ge XL, Wang CY, Guo W, Tang YL, et al. Pneumonia can cause clozapine intoxication: a case report. Psychosomatics. 2017;58(6):652–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28669537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruan CJ, Zang YN, Cheng YH, Wang CY, de Leon J. Around 3% of 1300 levels were elevated during infections in a retrospective review of 131 Beijing hospital in-patients with more than 24,000 days of clozapine treatment. Psychother Psychosom. 2020;89(4):255–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32114581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiao Z, Zhong MK, Shi XJ, Hu M, Zhang JH. Population pharmacokinetics of carbamazepine in Chinese epilepsy patients. Ther Drug Monit. 2003;25(3):279–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12766553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Botts S, Littrell R, de Leon J. Variables associated with high olanzapine dosing in a state hospital. J Clin Psychiatry. 2004;65(8):1138–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15323601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz FJ, Josiassen RC, de Leon J. The effect of body weight changes on total plasma clozapine concentrations determined by applying a statistical model to the data from a double-blind trial. J Clin Psychopharmacol. 2018;38(5):442–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30106876</ArticleId>
            <ArticleId IdType="pmc">6113094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang WH, Lin SK, Lane HY, Hu WH, Jann MW, Lin HN. Clozapine dosages and plasma drug concentrations. J Formos Med Assoc. 1997;96:599–605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9290269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chong SA, Tan CH, Khoo YM, Lee HS, Wong KE, Ngui F, Winslow M. Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia. Ther Drug Monit. 1997;19:219–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9108654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng CH, Chong SA, Lambert T, Fan A, Hackett LP, Mahendran R, Subramaniam M, Schweitzer I. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol. 2005;20:163–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15812267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spina E, de Leon J. Clinical applications of CYP genotyping in psychiatry. J Neural Transm (Vienna). 2015;122:5–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25200585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruan CJ, Wang CY, Tang YL, Lin SK, Lee ST, Hong KS, Rajkumar AP, Jacob KS, de Leon J. Exploring the prevalence of clozapine phenotypic poor metabolizers in 4 Asian samples: they ranged between 2% and 13. J Clin Psychopharmacol. 2019;39(6):644–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31688448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>González-Esquivel DF, Jung-Cook H, Baptista T, de Leon J. Amerindians may need clozapine dosing similar to that of Asians. Rev Psiquiatr Salud Ment. 2020;28:S1888-9891 (Epub ahead of print).</Citation>
        </Reference>
        <Reference>
          <Citation>de Leon J, Rajkumar AP, Kaithi AR, Schoretsanitis G, Kane JM, Wang CY, Tang YL, Lin SK, Hong KS, Farooq S, Ng CH, Ruan CJ, Andrade C. Do Asian patients require only half of the clozapine dose prescribed for Caucasians? A critical overview. Indian J Psychol Med. 2020;42(1):4–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31997860</ArticleId>
            <ArticleId IdType="pmc">6970303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Leon J, Ruan CJ, Schoretsanitis G, Kane JM. Dose and safety concerns of clozapine: worldwide package inserts need revisions. Schizophr Res. 2020;216:2–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31926811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sathirakul K, Chan C, Teng L, Bergstrom RF, Yeo KP, Wise SD. Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects. Br J Clin Pharmacol. 2003;56(2):184–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12895191</ArticleId>
            <ArticleId IdType="pmc">1884282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruan CJ, de Leon J. Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine? Pharmacogenomics. 2020;21(6):369–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32308139</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
